Harvard scholars call to eliminate orphan drug exemption in IRA to save Medicare more
While biopharma companies are calling foul over the fact that blockbuster drugs with multiple orphan designations remain eligible for government price negotiations under the Inflation Reduction Act, Harvard researchers are calling on Congress to do away with the current exemption for drugs with only a single orphan designation.
Such a move by Congress, according to the authors of a new JAMA Internal Medicine paper, could save billions more dollars on top of what the IRA is currently saving by Medicare negotiating the prices of the most expensive biologics and small molecule drugs.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.